| Trial ID: | L2985 |
| Source ID: | NCT02256189
|
| Associated Drug: |
Sitagliptin
|
| Title: |
Sitagliptin and Glucagon Counterregulation
|
| Acronym: |
SITACLAMP
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT02256189/results
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: Sitagliptin|DRUG: Placebo
|
| Outcome Measures: |
Primary: Glucagon Counterregulation to Hypoglycemia, Change in plasma glucagon to insulin-induced hypoglycemia after four weeks of treatment with sitagliptin and placebo, Four weeks treatment |
|
| Sponsor/Collaborators: |
Sponsor: Lund University | Collaborators: Merck Sharp & Dohme LLC
|
| Gender: |
ALL
|
| Age: |
OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
28
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE
|
| Start Date: |
2015-04
|
| Completion Date: |
2017-06
|
| Results First Posted: |
2019-02-20
|
| Last Update Posted: |
2019-02-20
|
| Locations: |
Skane University Hospital Malmö, Malmö, 20502, Sweden
|
| URL: |
https://clinicaltrials.gov/show/NCT02256189
|
